Avalo Therapeutics (AVTX) News Today $6.75 +0.02 (+0.30%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Drops By 11.8%Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) saw a large drop in short interest in the month of December. As of December 31st, there was short interest totalling 20,200 shares, a drop of 11.8% from the December 15th total of 22,900 shares. Currently, 0.2% of the company's shares are short sold. Based on an average daily trading volume, of 84,800 shares, the days-to-cover ratio is currently 0.2 days.January 17 at 6:30 PM | marketbeat.comAvalo Therapeutics (NASDAQ:AVTX) Shares Up 6.5% - Time to Buy?January 17 at 2:43 AM | americanbankingnews.comAvalo Therapeutics (NASDAQ:AVTX) Stock Price Up 6.5% - Still a Buy?Avalo Therapeutics (NASDAQ:AVTX) Stock Price Up 6.5% - Here's WhyJanuary 17 at 2:40 AM | marketbeat.comAvalo Therapeutics Appoints Jennifer Riley As Chief Strategy Officer, Stock DownJanuary 2, 2025 | markets.businessinsider.comAvalo Therapeutics Appoints Jennifer Riley as Chief Strategy OfficerJanuary 2, 2025 | globenewswire.comAvalo Therapeutics (AVTX) Has a New Rating from BTIGDecember 30, 2024 | markets.businessinsider.comShort Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Increases By 340.4%Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) was the recipient of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 22,900 shares, a growth of 340.4% from the November 30th total of 5,200 shares. Currently, 0.3% of the company's shares are sold short. Based on an average daily volume of 74,100 shares, the days-to-cover ratio is presently 0.3 days.December 26, 2024 | marketbeat.comAvalo Therapeutics initiated with a Buy at BTIGDecember 21, 2024 | markets.businessinsider.comBTIG Initiates Coverage of Avalo Therapeutics (AVTX) with Buy RecommendationDecember 21, 2024 | msn.comBTIG Research Begins Coverage on Avalo Therapeutics (NASDAQ:AVTX)BTIG Research initiated coverage on Avalo Therapeutics in a research report on Thursday. They set a "buy" rating and a $40.00 price target for the company.December 19, 2024 | marketbeat.comLUCID CAPITAL MARKETS Initiates Coverage of Avalo Therapeutics (AVTX) with Buy RecommendationDecember 18, 2024 | msn.comAvalo Therapeutics, Inc. (NASDAQ:AVTX) Sees Large Drop in Short InterestAvalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) was the target of a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 5,200 shares, a decrease of 46.9% from the November 15th total of 9,800 shares. Currently, 0.1% of the company's shares are short sold. Based on an average daily volume of 45,100 shares, the short-interest ratio is currently 0.1 days.December 12, 2024 | marketbeat.comRA Capital Management L.P. Invests $9.19 Million in Avalo Therapeutics, Inc. (NASDAQ:AVTX)RA Capital Management L.P. purchased a new position in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund purchased 967,000 shares of the company's stock, valued at approximately $9,186,000. RADecember 5, 2024 | marketbeat.comAvalo Therapeutics receives $69.4M in proceeds from exercise of warrantsNovember 12, 2024 | markets.businessinsider.comAvalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement WarrantsNovember 12, 2024 | globenewswire.comAvalo Therapeutics to Present at Upcoming Investor ConferencesNovember 11, 2024 | globenewswire.comOppenheimer Remains a Buy on Avalo Therapeutics (AVTX)November 9, 2024 | markets.businessinsider.comAvalo Therapeutics (AVTX) Receives a Hold from H.C. WainwrightNovember 9, 2024 | markets.businessinsider.comAvalo Reports Third Quarter 2024 Financial Results and Recent Business UpdatesNovember 7, 2024 | finance.yahoo.comHC Wainwright & Co. Initiates Coverage of Avalo Therapeutics (AVTX) with Neutral RecommendationOctober 24, 2024 | msn.comAvalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis SuppurativaOctober 8, 2024 | globenewswire.comAvalo Therapeutics (NASDAQ:AVTX) Stock, Short Interest ReportOctober 6, 2024 | benzinga.comAvalo Therapeutics (NASDAQ:AVTX) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comAvalo Therapeutics Inc. (C6K0.SG)September 19, 2024 | uk.finance.yahoo.comAvalo Announces Participation in September Investor ConferencesSeptember 4, 2024 | finance.yahoo.comThe 3 Best Personalized Nutrition Stocks to Buy NowJuly 24, 2024 | investorplace.comAvalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical OfficerJuly 16, 2024 | globenewswire.comAvalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis SuppurativaJuly 9, 2024 | globenewswire.comAvalo Therapeutics Announces Appointment of Paul Varki as Chief Legal OfficerJune 24, 2024 | globenewswire.comAvalo to Present at the Oppenheimer Novel Targets in Immunology SummitJune 17, 2024 | globenewswire.comAVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q1 2024May 13, 2024 | investorplace.comAvalo Therapeutics: Avalo Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 13, 2024 | finanznachrichten.deAvalo Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 13, 2024 | globenewswire.comOppenheimer Upgrades Avalo Therapeutics (AVTX)April 17, 2024 | msn.comAvalo Therapeutics (AVTX) Price Target Increased by 4566.67% to 35.70April 17, 2024 | msn.comWhy VirTra Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving PremarketApril 2, 2024 | benzinga.comAvalo Therapeutics Appoints Biotech Leaders to Board of DirectorsApril 2, 2024 | globenewswire.comAvalo Therapeutics Shares More than Triple After Co Acquires AlmataBioMarch 29, 2024 | marketwatch.comAvalo Reports 2023 Financial Results and Provides Business UpdatesMarch 29, 2024 | globenewswire.comAvalo Therapeutics: Avalo Acquires Anti-IL-1ß mAb and Announces Private Placement Financing of up to $185 MillionMarch 29, 2024 | finanznachrichten.deTrading was temporarily halted for "AVTX" at 03:03 PM with a stated reason of "LULD pause." Trading set to resume at 04:03 PM. March 28, 2024 | marketbeat.comMicro-Cap Avalo Therapeutics Stock Rallies As It Snaps AlmataBio For Ex-Eli Lilly Drug For Skin DisorderMarch 28, 2024 | msn.comTrading was temporarily halted for "AVTX" at 09:03 AM with a stated reason of "LULD pause."March 28, 2024 | marketbeat.comWhy Is Avalo Therapeutics (AVTX) Stock Up 326% Today?March 28, 2024 | investorplace.comAvalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 MillionMarch 27, 2024 | globenewswire.comAvalo (AVTX) to Report Q4 Earnings: What's in the Cards?February 26, 2024 | finance.yahoo.comAvalo Therapeutics Stock (NASDAQ:AVTX) Dividends: History, Yield and DatesJanuary 2, 2024 | benzinga.comTrading was temporarily halted for "AVTX" at 07:12 PM with a stated reason of "News pending."December 29, 2023 | marketbeat.comAvalo Therapeutics announces a 1-for-240 reverse stock splitDecember 27, 2023 | msn.comAvalo Therapeutics Announces 1-for-240 Reverse Stock SplitDecember 27, 2023 | finance.yahoo.com Get Avalo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address AVTX Media Mentions By Week AVTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AVTX News Sentiment▼0.910.44▲Average Medical News Sentiment AVTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AVTX Articles This Week▼31▲AVTX Articles Average Week Get Avalo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Aquestive Therapeutics News Today Immutep News Today Y-mAbs Therapeutics News Today Olema Pharmaceuticals News Today Neurogene News Today Rezolute News Today Atyr PHARMA News Today Compass Therapeutics News Today Atea Pharmaceuticals News Today AC Immune News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AVTX) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
